Literature DB >> 18397888

The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Elisa Greggio1, Ibardo Zambrano, Alice Kaganovich, Alexandra Beilina, Jean-Marc Taymans, Veronique Daniëls, Patrick Lewis, Shushant Jain, Jinhui Ding, Ali Syed, Kelly J Thomas, Veerle Baekelandt, Mark R Cookson.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial and apparently sporadic Parkinson disease. LRRK2 is a multidomain protein kinase with autophosphorylation activity. It has previously been shown that the kinase activity of LRRK2 is required for neuronal toxicity, suggesting that understanding the mechanism of kinase activation and regulation may be important for the development of specific kinase inhibitors for Parkinson disease treatment. Here, we show that LRRK2 predominantly exists as a dimer under native conditions, a state that appears to be stabilized by multiple domain-domain interactions. Furthermore, an intact C terminus, but not N terminus, is required for autophosphorylation activity. We identify two residues in the activation loop that contribute to the regulation of LRRK2 autophosphorylation. Finally, we demonstrate that LRRK2 undergoes intramolecular autophosphorylation. Together, these results provide insight into the mechanism and regulation of LRRK2 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397888      PMCID: PMC2423262          DOI: 10.1074/jbc.M708718200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction.

Authors:  Zhexin Xiang; Cinque S Soto; Barry Honig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 2.  Regulation of protein kinases; controlling activity through activation segment conformation.

Authors:  Brad Nolen; Susan Taylor; Gourisankar Ghosh
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

3.  Identification of potential protein interactors of Lrrk2.

Authors:  Justus C Dächsel; Julie P Taylor; Su San Mok; Owen A Ross; Kelly M Hinkle; Rachel M Bailey; Jacob H Hines; Jennifer Szutu; Benjamin Madden; Leonard Petrucelli; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2007-04-02       Impact factor: 4.891

4.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

5.  The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation.

Authors:  I W Leung; N Lassam
Journal:  J Biol Chem       Date:  2000-10-26       Impact factor: 5.157

6.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

Authors:  Manabu Funayama; Kazuko Hasegawa; Hisayuki Kowa; Masaaki Saito; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

7.  Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1 oligomerization.

Authors:  Jae J Song; Yong J Lee
Journal:  J Biol Chem       Date:  2003-09-10       Impact factor: 5.157

8.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.

Authors:  Luxuan Guo; Payal N Gandhi; Wen Wang; Robert B Petersen; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Exp Cell Res       Date:  2007-07-19       Impact factor: 3.905

9.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  148 in total

1.  GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.

Authors:  Ruibai Luo; Itoro O Akpan; Ryo Hayashi; Marek Sramko; Valarie Barr; Yoko Shiba; Paul A Randazzo
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

Review 2.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

3.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

4.  Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy.

Authors:  Jason Schapansky; Jonathan D Nardozzi; Fredrik Felizia; Matthew J LaVoie
Journal:  Hum Mol Genet       Date:  2014-03-27       Impact factor: 6.150

5.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

6.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

7.  Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.

Authors:  Giambattista Guaitoli; Francesco Raimondi; Bernd K Gilsbach; Yacob Gómez-Llorente; Egon Deyaert; Fabiana Renzi; Xianting Li; Adam Schaffner; Pravin Kumar Ankush Jagtap; Karsten Boldt; Felix von Zweydorf; Katja Gotthardt; Donald D Lorimer; Zhenyu Yue; Alex Burgin; Nebojsa Janjic; Michael Sattler; Wim Versées; Marius Ueffing; Iban Ubarretxena-Belandia; Arjan Kortholt; Christian Johannes Gloeckner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

8.  Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.

Authors:  Ravindra Boddu; Travis D Hull; Subhashini Bolisetty; Xianzhen Hu; Mark S Moehle; João Paulo Lima Daher; Ahmed Ibrahim Kamal; Reny Joseph; James F George; Anupam Agarwal; Lisa M Curtis; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-22       Impact factor: 6.150

Review 9.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

10.  Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Authors:  Eva Andres-Mateos; Rebeca Mejias; Masayuki Sasaki; Xiaojie Li; Brian M Lin; Saskia Biskup; Li Zhang; Rebecca Banerjee; Bobby Thomas; Lichuan Yang; Guosheng Liu; M Flint Beal; David L Huso; Ted M Dawson; Valina L Dawson
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.